Progyny Inc (PGNY US) shares touched new high after the company issued 2022 revenue growth guidance of 50%. The company has added record high number of new clients and new covered lives.
The company reported Q3 revenue of $122.3 million (+24% y/y), in-line with guidance of $120–130 million. EPS grew 240% y/y to $0.17, 183% ahead of consensus of $0.06. Progyny expects 2021 revenue growth of 47–49% y/y.
Investors can add to positions as Progyny is expected to be on a high growth trajectory as the company is still just 2% penetrated in its addressable market of 8,000 self-insured employers in the U.S., leaving enough growth opportunity.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.